In This Section

Program

Program in Progress
(as of May 10, 2021)

KEYNOTE LECTURES AND SPECIAL SESSIONS

K01: ctDNA and low dose CT for early-stage lung cancer screening
Samuel Janes, University College London, London, England

K02: CRISPR and gene modification for cancer therapeutics
Jennifer A. Doudna, UC Berkeley, Berkeley, California

SP01: Closing Session: What is the Biggest Roadblock in Anticancer Drug Development in the Next Decade and What Can be Done to Mitigate?
Moderator: Jean-Charles Soria, Institut Gustave Roussy, Villejuif, France

Plenary sessions

PL01: Antibody Drug Conjugates, Peptide Conjugates, and Bi-Cyclics
Cochairs: Puja Sapra, AstraZeneca, Gaithersburg, Maryland, and Stefan N. Symeonides, University of Edinburgh, Edinburgh, Scotland

PL02: New Drugs on the Horizon
Cochairs: James L. Gulley, National Cancer Institute, Bethesda, Maryland, and Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, ON, Canada

PL03: Bispecific T cell Engagers and Next-gen CAR T Therapies: Pros and Cons of These Strategies
Cochairs: Kapil Dhingra, KAPital Consulting LLC, Sparta, New Jersey, and Jeffrey A. Moscow, National Cancer Institute, Bethesda, Maryland

PL04: DNA Damage Response Beyond PARP
Cochairs: Ruth Plummer, Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom, and Ioannis Gounaris, Merck-Serono Ltd., Feltham, United Kingdom

PL05: Drugging Difficult Targets
Cochairs: Fiona H. Blackhall, University of Manchester, Manchester, England, and Pasi A. Jänne, Dana-Farber Cancer Institute, Boston, Massachusetts

PL06: HER2-directed Therapies – Dedicated to the Memory of José Baselga
Cochairs: Carlos L. Arteaga, UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, Texas, and Martine J. Piccart, Institut Jules Bordet, Brussels

PL07: Non T-cell Therapies
Cochairs: Rosandra N. Kaplan, National Cancer Institute, Bethesda, Maryland, and additional Cochair to be announced

PL08: Protein Degraders and Molecular Glues
Cochairs: Susan M. Galbraith, AstraZeneca, Cambridge, England, and additional Cochair to be announced

Concurrent sessions

CC01: Clinical Utility and Applications of New Computational Technologies
Cochairs: Benjamin Haibe-Kains, UHN Princess Margaret Cancer Centre, Toronto, ON, Canada, and Kenna R. Mills Shaw, The University of Texas MD Anderson Cancer Center, Houston, Texas

CC02: Drugs Targeting Metabolism
Cochairs: Stanley Lipkowitz, National Cancer Institute, Bethesda, Maryland, and additional Cochair to be announced

CC03: Extracellular Vesicles as Therapeutic Targets
Cochairs: Toby T. Hecht, National Cancer Institute, Rockville, Maryland, and Jennifer C. Jones, National Cancer Institute, Bethesda, Maryland

CC04: Novel Precision Medicine Combination Trials
Cochairs: James H. Doroshow, National Cancer Institute, Bethesda, Maryland, and Elena Garralda, Vall D’Hebron Institute of Oncology, Barcelona, Spain

CC05: Preclinical Models and Predictive Value
Cochairs: Lori S. Friedman, ORIC Pharmaceuticals, South San Francisco, California, and Zoë Weaver Ohler, NCI-Frederick/Leidos Biomedical Research, Inc., Frederick, Maryland

CC06: Radiopharmaceuticals Coming of Age
Cochairs: Beverly A. Teicher, National Cancer Institute, Bethesda, Maryland, and additional Cochair to be announced

CC07: Targeting Molecular Residual Disease with ctDNA Technologies
Cochairs: Benjamin Besse, Institut Gustave Roussy, Villejuif, France, and Jeanne Tie, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

CC08: Tumor Microbiome
Cochairs: Tim F. Greten, National Cancer Institute, Bethesda, Maryland, and Laurence Zitvogel, Institute Gustave Roussy, Villejuif, France

CC09: Topic to be announced

Educational sessions

ED01: Exploiting Synthetic Lethality
Cochairs: Eytan Ruppin, National Cancer Institute, Bethesda, Maryland, and Barbara Weber, Tango Therapeutics, Boston, Massachusetts

ED02: Novel Clinical Trial Designs and Development of Next-gen Investigators for Complex Anticancer Agents
Cochairs: Philippe L. Bedard, UHN Toronto General Hospital, Toronto, ON, Canada, and Laura J. Esserman, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California